-
Start Preamble
AGENCY:
Drug Enforcement Administration (DEA), Justice.
ACTION:
Notice of aggregate production quotas for 2010.
SUMMARY:
This notice establishes initial 2010 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA).
DATES:
Effective Date: October 21, 2009.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D, Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104.
The 2010 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 2010 to provide adequate supplies of each substance for: the estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks (21 U.S.C. 826(a) and 21 CFR 1303.11). These quotas do not include imports of controlled substances for use in industrial processes.
On May 21, 2009, a notice of the proposed initial 2010 aggregate production quotas for certain controlled substances in schedules I and II was published in the Federal Register (74 FR 23881). All interested persons were invited to comment on or object to these proposed aggregate production quotas on or before June 22, 2009.
Twelve responses (eleven from DEA registered manufacturers, and one from a non-DEA registrant) were received within the published comment period, offering comments on a total of 28 schedule I and II controlled substances. One additional comment was received after the comment period ended and therefore was not considered. The commenters stated that the proposed aggregate production quotas for 3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, 3,4-methylenedioxymethamphetamine, alfentanil, amphetamine (for sale), codeine (for sale), codeine (for conversion), dihydromorphine, fentanyl, gamma hydroxybutyric acid, hydrocodone, hydromorphone, isomethadone, levo-desoxyephedrine, levorphanol, lisdexamfetamine, methamphetamine (for sale), morphine (for conversion), nabilone, opium (tincture), oxycodone (for sale), oxycodone (for conversion), oxymorphone (for sale), remifentanil, sufentanil, tapentadol, tetrahydrocannabinols, and thebaine were insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.
In arriving at the aggregate production quotas, DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11(b) and other relevant 2009 factors, including 2009 manufacturing quotas, current 2009 sales and inventories, 2010 export requirements, additional applications received, and research and product development requirements. Based on this information, DEA has adjusted the initial aggregate production quotas for 4-methoxyamphetamine, alpha-methyltryptamine, amphetamine (for conversion), dihydromorphine, isomethadone, levo-desoxyephedrine, lisdexamfetamine, lysergic acid diethylamide, methamphetamine (for sale), methamphetamine (for conversion), methaqualone, oxycodone (for sale), oxycodone (for conversion), oxymorphone (for sale) and phenylacetone to meet the legitimate needs of the United States.
DEA proposed the aggregate production quota for tapentadol at 519,000 g in the 2010 proposed initial aggregate production quota notice published on May 21, 2009 in the Federal Register (74 FR 23881). Tapentadol is no longer listed because the material will be imported into the United States and not manufactured domestically.
Regarding 3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, 3,4-methylenedioxymethamphetamine, alfentanil, amphetamine (for sale), codeine (for sale), codeine (for conversion), fentanyl, gamma hydroxybutyric acid, hydrocodone, hydromorphone, levorphanol, morphine (for conversion), nabilone, opium (tincture), remifentanil, sufentanil, tetrahydrocannabinols, and thebaine DEA has determined that the proposed initial 2010 aggregate production quotas are sufficient to meet the current 2010 estimated medical, scientific, research and industrial needs of the United States.
Pursuant to 21 CFR 1303, the Deputy Administrator of DEA will, in 2010, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 2009 year-end inventory and actual 2009 disposition data supplied by quota recipients for each basic class of schedule I or II controlled substance.Start Printed Page 54081
Therefore, under the authority vested in the Attorney General by Section 306 of the CSA (21 U.S.C. 826), and delegated to the Administrator of DEA by 28 CFR § 0.100, and redelegated to the Deputy Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby orders that the 2010 initial aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:
Start Printed Page 54082Basic class—Schedule I Established 2010 quotas 2,5-Dimethoxyamphetamine 2 g 2,5-Dimethoxy-4-ethylamphetamine (DOET) 2 g 3-Methylfentanyl 2 g 3-Methylthiofentanyl 2 g 3,4-Methylenedioxyamphetamine (MDA) 25 g 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 10 g 3,4-Methylenedioxymethamphetamine (MDMA) 20 g 3,4,5-Trimethoxyamphetamine 2 g 4-Bromo-2,5-dimethoxyamphetamine (DOB) 2 g 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 2 g 4-Methoxyamphetamine 77 g 4-Methylaminorex 2 g 4-Methyl-2,5-dimethoxyamphetamine (DOM) 2 g 5-Methoxy-3,4-methylenedioxyamphetamine 2 g 5-Methoxy-N,N-diisopropyltryptamine 5 g Acetyl-alpha-methylfentanyl 2 g Acetyldihydrocodeine 2 g Acetylmethadol 2 g Allylprodine 2 g Alphacetylmethadol 2 g Alpha-ethyltryptamine 2 g Alphameprodine 2 g Alphamethadol 2 g Alpha-methylfentanyl 2 g Alpha-methylthiofentanyl 2 g Alpha-methyltryptamine 2 g Aminorex 2 g Benzylmorphine 2 g Betacetylmethadol 2 g Beta-hydroxy-3-methylfentanyl 2 g Beta-hydroxyfentanyl 2 g Betameprodine 2 g Betamethadol 2 g Betaprodine 2 g Bufotenine 3 g Cathinone 3 g Codeine-N-oxide 602 g Diethyltryptamine 2 g Difenoxin 3,000 g Dihydromorphine 3,300,000 g Dimethyltryptamine 3 g Gamma-hydroxybutyric acid 24,200,000 g Heroin 20 g Hydromorphinol 2 g Hydroxypethidine 2 g Ibogaine 1 g Lysergic acid diethylamide (LSD) 15 g Marihuana 4,500,000 g Mescaline 7 g Methaqualone 7 g Methcathinone 4 g Methyldihydromorphine 2 g Morphine-N-oxide 605 g N-Benzylpiperazine 2 g N,N-Dimethylamphetamine 7 g N-Ethylamphetamine 2 g N-Hydroxy-3,4-methylenedioxyamphetamine 2 g Noracymethadol 2 g Norlevorphanol 52 g Normethadone 2 g Normorphine 16 g Para-fluorofentanyl 2 g Phenomorphan 2 g Pholcodine 2 g Psilocybin 7 g Psilocyn 7 g Tetrahydrocannabinols 312,500 g Thiofentanyl 2 g Trimeperidine 2 g Basic class—Schedule II Established 2010 quotas 1-Phenylcyclohexylamine 2 g 1-piperdinocyclohexanecarbonitrile 2 g Alfentanil 8,000 g Alphaprodine 2 g Amobarbital 3 g Amphetamine (for sale) 17,000,000 g Amphetamine (for conversion) 6,500,000 g Cocaine 247,000 g Codeine (for sale) 39,605,000 g Codeine (for conversion) 65,000,000 g Dextropropoxyphene 106,000,000 g Dihydrocodeine 1,200,000 g Diphenoxylate 947,000 g Ecgonine 83,000 g Ethylmorphine 2 g Fentanyl 1,428,000 g Glutethimide 2 g Hydrocodone (for sale) 55,000,000 g Hydromorphone 3,300,000 g Isomethadone 11 g Levo-alphacetylmethadol (LAAM) 3 g Levomethorphan 5 g Levorphanol 10,000 g Lisdexamfetamine 9,000,000 g Meperidine 8,600,000 g Meperidine Intermediate-A 3 g Meperidine Intermediate-B 7 g Meperidine Intermediate-C 3 g Metazocine 1 g Methadone (for sale) 25,000,000 g Methadone Intermediate 26,000,000 g Methamphetamine 3,130,000 g [750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] Methylphenidate 50,000,000 g Morphine (for sale) 35,000,000 g Morphine (for conversion) 100,000,000 g Nabilone 9,002 g Noroxymorphone (for sale) 10,000 g Noroxymorphone (for conversion) 9,000,000 g Opium (powder) 230,000 g Opium (tincture) 1,050,000 g Oripavine 15,000,000 g Oxycodone (for sale) 88,000,000 g Oxycodone (for conversion) 4,000,000 g Oxymorphone (for sale) 2,570,000 g Oxymorphone (for conversion) 12,000,000 g Pentobarbital 28,000,000 g Phenazocine 1 g Phencyclidine 20 g Phenmetrazine 2 g Phenylacetone 12,500,001 g Racemethorphan 2 g Remifentanil 500 g Secobarbital 67,000 g Sufentanil 10,300 g Thebaine 126,000,000 g The Deputy Administrator further orders that aggregate production quotas for all other schedules I and II controlled substances included in 21 CFR 1308.11 and 1308.12 be established at zero.
The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132.
The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the Start Printed Page 54083establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.
This action meets the applicable standards set forth in Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $120,000,000 or more in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.
This action is not a major rule as defined by Section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This action will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.
Start SignatureEnd Signature End Supplemental InformationDated: October 14, 2009.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E9-25275 Filed 10-20-09; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 10/21/2009
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of aggregate production quotas for 2010.
- Document Number:
- E9-25275
- Pages:
- 54080-54083 (4 pages)
- Docket Numbers:
- DEA # 318E
- PDF File:
- e9-25275.pdf